{
  "nctrialId": "HC-1785",
  "title": "A  Double-Blind, Placebo-Controlled Multi-Center Study of AST-611 (anti-IL-5 antibody) in Patients With Systemic Lupus Erythematosus",
  "officialTitle": "A  Double-Blind, Placebo-Controlled Multi-Center Study of AST-611 (anti-IL-5 antibody) in Patients With Systemic Lupus Erythematosus",
  "sponsor": "BC Cancer Agency",
  "indication": "Systemic Lupus Erythematosus",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1785.json",
  "fileSize": 556313,
  "date": "2025-01-04",
  "completionDate": "2026-05-25",
  "drugName": "AST-611 (anti-IL-5 antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Recruiting",
  "description": "This is a  double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of AST-611 (anti-IL-5 antibody) in patients with Systemic Lupus Erythematosus. The study will enroll approximately 147 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-83 years\n- Confirmed diagnosis of Systemic Lupus Erythematosus\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n- Active disease defined by standard criteria\n- Inadequate response to conventional therapy\n- Positive serology (if applicable)\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment\n- Active infection including tuberculosis\n- History of recurrent serious infections\n- Concurrent autoimmune disease other than study indication",
  "csr_id": "HC-1785"
}